Fiorinal is a Schedule III controlled substance and Fioricet is not, even though both contain the same dose of the same barbiturate. The difference comes down to a single ingredient: aspirin versus acetaminophen. Federal rules from the 1960s determined that acetaminophen was dangerous enough in high doses to discourage people from abusing the drug, while aspirin was not.
Both Drugs Contain the Same Barbiturate
Fiorinal and Fioricet are remarkably similar. Both contain 50 mg of butalbital (a barbiturate) and 40 mg of caffeine. The only difference is the pain reliever: Fiorinal pairs butalbital with 325 mg of aspirin, while Fioricet uses 300 mg of acetaminophen instead. That one swap changes the legal classification entirely.
The “Counteractive Drug” Rule
In 1967, the DEA established criteria for exempting certain barbiturate combination products from controlled substance scheduling. The logic was straightforward: if a drug contains enough of a second ingredient that would make you sick before you could get high, the combination has lower abuse potential. The agency called these “counteractive drugs” because their side effects at high doses would deter misuse.
The specific formula required that for every 15 mg of barbiturate, the product needed at least 70 mg of acetaminophen (or 188 mg of aspirin) to qualify for exemption. At 50 mg of butalbital, Fioricet needed roughly 233 mg of acetaminophen. It contains 300 mg, clearing that bar easily. The reasoning was that anyone trying to take enough Fioricet to abuse the butalbital would also be swallowing dangerous amounts of acetaminophen, risking severe liver damage. That built-in danger was considered a sufficient deterrent.
Fiorinal, on the other hand, would have needed about 627 mg of aspirin per capsule to meet the exemption threshold. It contains only 325 mg. Because aspirin doesn’t cause the same kind of acute, organ-threatening toxicity at moderately high doses, the DEA set the aspirin requirement much higher. Fiorinal couldn’t meet it, so it stayed on Schedule III.
Why Acetaminophen Counts as a Deterrent
Acetaminophen is safe at recommended doses but becomes toxic relatively quickly when those doses climb. Taking large amounts over a short period can cause irreversible liver failure, and the damage sometimes doesn’t produce obvious symptoms until it’s too late to reverse. This steep jump from safe to dangerous is exactly what regulators were counting on. Someone chasing a barbiturate high from Fioricet would hit the acetaminophen danger zone well before reaching recreational levels of butalbital.
Aspirin, by contrast, causes stomach irritation and bleeding at high doses, but the consequences are generally less sudden and less catastrophic than acetaminophen-related liver failure. Regulators judged that aspirin’s side effects weren’t severe enough at the relevant doses to stop someone determined to misuse the product.
The Classification Is Controversial
Many clinicians and pharmacologists have questioned whether this distinction makes practical sense. Both products deliver the exact same barbiturate at the exact same dose, and the abuse potential of butalbital doesn’t change based on which pain reliever surrounds it. Butalbital can cause psychological dependence, physical tolerance, and severe withdrawal regardless of the formulation. A compulsive pattern of use can develop over weeks to months, particularly in people taking it frequently for recurring headaches.
The consequences of that dependence are serious. Barbiturate withdrawal can be life-threatening, producing seizures and other dangerous symptoms if the drug is stopped abruptly. Several countries, including the United Kingdom, France, Germany, and Australia, have pulled all butalbital combination products from their markets entirely because of these risks.
In the United States, some states have responded by overriding the federal exemption and classifying Fioricet as a controlled substance at the state level. If you live in one of these states, your pharmacy will treat a Fioricet prescription with the same restrictions as Fiorinal, including limits on refills and requirements for new prescriptions.
What This Means in Practice
Because Fiorinal is Schedule III, prescriptions typically can’t be refilled more than five times and expire six months after they’re written. Pharmacies must keep detailed records, and prescribers face tighter monitoring. Fioricet, where it remains exempt from scheduling, doesn’t carry those restrictions. It can be prescribed and refilled more like a standard medication, which makes it easier to obtain and, critics argue, easier to overuse.
The practical risk of both drugs is the same. Butalbital is habit-forming regardless of what it’s combined with, and people who take either medication regularly for headaches are at risk of developing medication overuse headaches, a cycle where the drug itself begins causing the pain it was meant to treat. The scheduling difference is a regulatory artifact from the 1960s, not a reflection of any real difference in how dangerous the two drugs are.